Theaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways

International Journal of Oncology

Volumn 48, Issue 1, 2016, Pages 281-292

  Gao, Ying ^a,b   Rankin, Gary O ^c   Tu, Youying ^a   Chen, Yi Charlie ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b Alderson Broaddus College   (United States)

^c MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3' digallate; A ktpathway; C Myc; Notch 1 pathway; Theaflavin 3; Tumor angiogenesis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN KINASE B; THEAFLAVIN 3,3' DIGALLATE; VASCULOTROPIN; BIFLAVONOID; CATECHIN; EPIGALLOCATECHIN GALLATE; HIF1A PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; ONCOPROTEIN; THEAFLAVIN-3,3'-DIGALLATE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL LINE; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA; DRUG EFFECTS; FEMALE; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BIFLAVONOIDS; CARCINOMA; CATECHIN; CELL LINE, TUMOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84953216319     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3257     Document Type: Article

References (57)

1. Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, Kunisada T, Yano M, Kuji S, Hirashima Y, et al: Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 137: 299-305, 2015.
2. Barakat RR, Markman M and Randall M: Principles and Practice of Gynecologic Oncology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, 2009.
3. Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet 384: 1376-1388, 2014.
4. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989.
5. Giri S, Karakoti A, Graham RP, Maguire JL, Reilly CM, Seal S, Rattan R and Shridhar V: Nanoceria: A rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS One 8: e54578, 2013.
6. Burger RA: Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 121: 230-238, 2011.
7. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
8. L iang YC, Chen YC, Lin YL , Lin-Shiau SY, Ho CT and Lin JK: Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3'-digallate. Carcinogenesis 20: 733-736, 1999.
9. Sajilata MG, Bajaj PR and Singhai RS: Tea polyphenols as nutraceuticals. Compr Rev Food Sci Food Saf 7: 229-254, 2008.
10. Tu YY , Tang AB and Watanabe N: The theaflavin monomers inhibit the cancer cells growth in vitro. Acta Biochim Biophys Sin (Shanghai) 36: 508-512, 2004.
11. Schuck AG, Ausubel MB, Zuckerbraun HL and Babich H: Theaflavin-3,3'-digallate, a component of black tea: an inducer of oxidative stress and apoptosis. Toxicol In Vitro 22: 598-609, 2008.
12. Gao Y, Li W, Jia L, Li B, Chen YC and Tu Y: Enhancement of (-)-epigallocatechin-3-gallate and theaflavin-3-3'-digallate induced apoptosis by ascorbic acid in human lung adenocarcinoma SPC-A-1 cells and esophageal carcinoma Eca-109 cells via MAPK pathways. Biochem Biophys Res Commun 438: 370-374, 2013.
13. Kobayashi S, Iwai S, Tsujiyama K, Kurahashi C, Udaka Y, Sanbe T, Suzaki H and Oguchi K: Theaflavin-3,3'-digallate inhibits tube formation in cocultured endothelial cells with fibroblasts. Showa Univ J Med Sci 19: 59-72, 2007.
14. Siddiqui IA, Zaman N, Aziz MH, Reagan-Shaw SR, Sarfaraz S, Adhami VM, Ahmad N, Raisuddin S and Mukhtar H: Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas. Carcinogenesis 27: 833-839, 2006.
15. Xu Y, Jin YX, Wu YY and Tu YY : Isolation and purification of four individual theaflavins using semi-preparative high performance liquid chromatography. J Liquid Chromatogr Relat Technol 33: 1791-1801, 2010.
16. Fang J, Xia C, Cao Z, Zheng JZ, Reed E and Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19: 342-353, 2005.
17. García-Maceira P and Mateo J: Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene 28: 313-324, 2009.
18. Chen C, Cai S, Wang G, Cao X, Yang X, Luo X, Feng Y and Hu J: c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1?. Biochem Biophys Res Commun 430: 505-511, 2013.
19. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA: The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23: 8571-8580, 2004.
20. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, et al: c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20: 2096-2109, 2006.
21. Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, et al: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 68: 81-88, 2008.
22. Baker JA, Boakye K, McCann SE, Beehler GP, Rodabaugh KJ, Villella JA and Moysich KB: Consumption of black tea or coffee and risk of ovarian cancer. Int J Gynecol Cancer 17: 50-54, 2007.
23. Banerjee P, Banerjee S and Mazumder S: Effect of theaflavin, A black tea extract on ovarian cancer cell line. Bombay Hosp J 53: 341-348, 2011.
24. Maity S, Ukil A, Vedasiromoni JR and Das PK: Biodistribution and pharmacokinetics of theaflavin-3,3'-digallate, the major antioxidant of black tea, in mice. Int J Pharmacol 2: 240-246, 2006.
25. Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO and Chen Y C: Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. J Funct Foods 15: 464-475, 2015.
26. Chen J, Chen AY, Huang H, Ye X, Rollyson WD, Perry HE, Brown KC, Rojanasakul Y, Rankin GO, Dasgupta P, et al: The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway. Int J Oncol 46: 2629-2638, 2015.
27. Schoell WM, Pieber D, Reich O, Lahousen M, Janicek M, Guecer F and Winter R: Tumor angiogenesis as a prognostic factor in ovarian carcinoma: Quantification of endothelial immunoreactivity by image analysis. Cancer 80: 2257-2262, 1997.
28. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR and Tortora G: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465, 2001.
29. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580, 2004.
30. Zhu LQ, Liu J and Ma CJ: Effect of theaflavin diagallate on anti-tumor proliferation and VEGF gene expression in lung adenocancer A549 cells. Cent S Pharm 9: 23-26, 2011.
31. Jung YD and Ellis LM: Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 82: 309-316, 2001.
32. Su YL , Leung LK, Huang Y and Chen ZY: Stability of tea theaflavins and catechins. Food Chem 83: 189-195, 2003.
33. Y ang ZY, Tu YY , Xia HL, Jie GL, Chen XM and He PM: Suppression of free-radicals and protection against H2O2-induced oxidative damage in HPF-1 cell by oxidized phenolic compounds present in black tea. Food Chem 105: 1349-1356, 2007.
34. Gu JW, Makey KL, Tucker KB, Chinchar E, Mao X, Pei I, Thomas EY and Miele L: EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1 and NFB, and VEGF expression. Vasc Cell 5: 9, 2013.
35. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J and Le AD: Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia-and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5: 1227-1238, 2006.
36. Li W, Tan D, Zhang Z, Liang JJ and Brown RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 20: 713-719, 2008.
37. L i G, Shan C, Liu L, Zhou T, Zhou J, Hu X, Chen Y, Cui H and Gao N: Tanshinone IIA inhibits HIF-1 and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. PLoS One 10: e0117440, 2015.
38. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L and Jiang BH: MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 40: 761-774, 2012.
39. Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al: Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 7: e47516, 2012.
40. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN and Cleveland JL: c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 16: 2530-2543, 2002.
41. L ee JG and Wu R: Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1 in EGFRmutated lung cancer in vitro and in vivo. Neoplasia 17: 190-200, 2015.
42. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB and Schwartz GK: gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69: 573-582, 2009.
43. Garcia A and Kandel JJ: Notch: A key regulator of tumor angiogenesis and metastasis. Histol Histopathol 27: 151-156, 2012.
44. Guo D, Li C, Teng Q, Sun Z, Li Y and Zhang C: Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma. Neoplasma 60: 33-40, 2013.
45. Proia T, Jiang F, Bell A, Nicoletti R, Kong L, Kreuter K, Poling L , Winston WM, Flaherty M, Weiler S, et al: 23814, an inhibitory antibody of ligand-mediated Notch1 activation, modulates angiogenesis and inhibits tumor growth without gastrointestinal toxicity. Mol Cancer Ther 14: 1858-1867, 2015.
46. Y an B, Zhou Y, Feng S, et al: beta-elemene-attenuated tumor angiogenesis by targeting Notch-1 in gastric cancer stem-like cells. J Evid Based Complementary Altern Med 2013: 268468, 2013.
47. Rose SL, Kunnimalaiyaan M, Drenzek J and Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol Oncol 117: 130-133, 2010.
48. Shankar S, Chen Q and Srivastava RK: Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3: 7, 2008.
49. Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A, Kollipara R, DePinho RA, Zeiher AM and Dimmeler S: Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 115: 2382-2392, 2005.
50. Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, Mukai H, Iwashita S, Kako K, Kishi T, Kasuya Y, et al: Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal 19: 519-527, 2007.
51. L am EW, Francis RE and Petkovic M: FOXO transcription factors: Key regulators of cell fate. Biochem Soc Trans 34: 722-726, 2006.
52. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, Bucana CD, Gallick GE and Ellis LM: EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84: 844-850, 2001.
53. Shankar S, Marsh L and Srivastava RK: EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol Cell Biochem 372: 83-94, 2013.
54. Wang F, Chang Z, Fan Q and Wang L: Epigallocatechin3gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase2. Mol Med Rep 9: 1085-1089, 2014.
55. Jhoo JW, Lo CY, Li S, Sang S, Ang CY, Heinze TM and Ho CT: Stability of black tea polyphenol, theaflavin, and identification of theanaphthoquinone as its major radical reaction product. J Agric Food Chem 53: 6146-6150, 2005.
56. Sang S, Lambert JD, Tian S, Hong J, Hou Z, Ryu JH, Stark RE, Rosen RT, Huang MT, Yang CS, et al: Enzymatic synthesis of tea theaflavin derivatives and their anti-inflammatory and cytotoxic activities. Bioorg Med Chem 12: 459-467, 2004.
57. Park HY, Kunitake Y and Matsui T: Benzotropolone moiety in theaflavins is responsible for inhibiting peptide-transport and activating AMP-activated protein kinase in Caco-2 cells. Funct Foods Health Dis 3: 111-121, 2013.